Theriva reports positive VIRAGE Phase 2b data for VCN-01 in pancreatic cancer at AACR 2026

Theriva Biologics, Inc.

VCN-01 + gemcitabine/nab-paclitaxel improved OS and PFS vs GnP alone in metastatic pancreatic cancer patients.
Later-emerging, higher magnitude, more durable responses observed; benefit maintained across subgroups including liver metastases.
Patients receiving a second VCN-01 dose showed greater OS and PFS benefit.
CEO reported alignment with FDA and EMA on proposed pivotal Phase 3 trial; planning study of more frequent VCN-01 dosing.
Data presented at AACR 2026 (poster CT162) on April 20, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.